Finoriq research workspace
Royalty Pharma plc (RPRX) Institutional Holdings & 13F Ownership
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of. Review RPRX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
- Company
- Royalty Pharma plc (RPRX)
- Ticker
- RPRX
- Market Cap
- $33.2B
- Latest Price
- $57.58
- Industry
- Biotech & Pharma
Royalty Pharma plc (RPRX) Top Institutional Holders
Top current 13F holders indexed for Royalty Pharma plc (RPRX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Samantha McLemoreCIK 0001854794 | $174.8M | 6.4% | Filing2026-05-14 |
| 2 | Pat DorseyCIK 0001671657 | $109.2M | 8.7% | Filing2026-05-15 |
| 3 | Torray FundsCIK 0000098758 | $31M | 4.5% | Filing2026-05-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.